$VERX

Vertex (VERX) Q2 2026 Earnings Call Transcript

Vertex, Inc. (VERX) reported Q2 2026 revenue of $204 million, up 10.5% year over year and at the high end of guidance. Adjusted EBITDA rose 33% to $51 million, with margin expanding to 25.0%. Subscription revenue grew to $174.8 million and ARR reached $703.4 million. Full-year revenue guidance was narrowed to $825-$830 million and adjusted EBITDA guidance raised to $206-$210 million.

Original reporting
Published Aug 11, 2026, 3:45 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 11, 2026, 4:08 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Vertex (VERX) Q2 2026 Earnings Call Transcript — source image
Decision brief

The 30-second read

$VERXBullishMed
01

Why it matters

Traders can update expectations for FY revenue and profitability after the company narrowed revenue guidance, increased adjusted EBITDA guidance, and guided Q3 revenue and EBITDA ranges. The key debate is whether slower cloud conversions are temporary timing shifts or a longer demand/execution issue.

02

Market read

The article provides fresh guidance and operational metrics (ARR, NRR, cloud conversion timing, AI adoption) that can drive near-term positioning into Q3 and FY.

03

What to watch

ARR growth is solid but NRR is down vs last year (108% to 105%), which could foreshadow future expansion pressure if conversions do not accelerate.

Relevance 8/10Novelty 8/10Timing: post-earnings call, pre-next-quarter setup

Background

This is a transcript-style summary of Vertex’s Q2 2026 earnings call, covering results, guidance, and management commentary on AI and cloud conversion.

Company-level read

Ticker impact

$VERXBullishMedium confidence
Context

Vertex reported Q2 revenue of $204M at the high end of guidance and raised full-year adjusted EBITDA to $206M-$210M.

Expected impact

Bias to support the stock on margin and guidance raise, with caution on cloud conversion-driven revenue timing.

Evidence & confidence

The article includes multiple fresh, decision-relevant datapoints: Q2 beat vs guidance on adjusted EBITDA, narrowed revenue range, increased adjusted EBITDA guidance, and explicit cloud conversion timing headwind.

Market effects

Signals continued demand for AI-enabled tax compliance software, but highlights execution risk in cloud conversion timing.

E-invoicing momentum includes mandates in France and Finland, supporting European compliance software demand.

Reinforces that government e-invoicing mandates remain the primary driver of compliance software adoption globally.

Counterpoint

Cloud revenue growth is projected at 18% with conversion timing issues, so the revenue profile may lag even if margins improve.

Key entities

  • Vertex, Inc.

    Reported Q2 results, narrowed FY revenue guidance, increased FY adjusted EBITDA guidance, and discussed AI adoption and cloud conversion timing.

  • Christopher Young

    CEO who attributed compliance buying to government mandates and discussed AI-driven operational gains.

  • John Schwab

    CFO who characterized slower cloud migration as conversion timing rather than revenue loss.

Related articles

$VERXMedAI 8/10

Vertex Raises Profit Outlook as Cloud Revenue Climbs 18%

Vertex (NASDAQ: VERX) raised its 2026 adjusted EBITDA outlook to $206M-$210M after Q2 revenue rose 10.5% to $204M and cloud revenue grew 17.9% to $101.7M. Full-year revenue guidance was narrowed to $825M-$830M, with 18% cloud growth expected. Q2 adjusted EBITDA rose 32.8% to $51M.

$VERXMedAI 8/10

Vertex Q2 Earnings Call Highlights

Vertex (NASDAQ:VERX) said slower cloud conversion is a timing issue, with customers using mixed cloud and on-prem deployments. Management highlighted strong e-invoicing momentum ahead of France and Germany mandates, expecting e-invoicing to affect ARR in Q3 and more in Q4. Q3 guidance: revenue $208M-$211M, adj. EBITDA $55M-$57M; full-year revenue $825M-$830M and adj. EBITDA $206M-$210M.

$VERXMedAI 8/10

Why is Vertex stock sliding today?

Vertex Pharmaceuticals shares fell 12.8% after its post-close Q2 2026 results. The company reported EPS of $0.20 vs $0.19 consensus and revenue of $203.97M vs $202.29M forecast, but Q3 2026 revenue guidance of $208M-$211M (midpoint below ~$211.69M consensus) and free cash flow of $2.7M disappointed. Morgan Stanley downgraded to Equal Weight and cut its price target to $15 from $19.